COVID ‐19: immunopathology, pathophysiological mechanisms, and treatment options
COVID-19: иммунопатология, патофизиологические механизмы и варианты лечения
2021-02-16
SCID: 54.1/d7m4ptq2
Discuss with AI
COVID-19 immunopathologyCOVID-19 vaccinesSARS-CoV-2 infectionacute respiratory distress syndromemulti-organ failure
Figures from the paper
Abstract (AI)
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID-19 cases are characterised by a mild, self-limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi-organ failure (MOF). Progression of COVID-19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS-CoV-2 infection and contribute to organ-specific tissue damage. In this respect, dissecting currently available knowledge of COVID-19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune-mediated pathways during SARS-CoV-2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID-19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence-based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID-19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID-19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID-19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Key Findings
1
COVID-19 severity ranges from mild, self-limiting illness to pneumonia, acute respiratory distress syndrome, and multi-organ failure.
2
Current management combines supportive care with repurposed or symptomatic therapies, including dexamethasone, remdesivir, and anticoagulants.
3
Disease progression reflects interactions among innate immunity, adaptive immunity, autoimmunity, and other pathophysiological mechanisms that drive organ-specific tissue damage.
4
Effective prevention depends primarily on measures that reduce transmission and the development and implementation of effective vaccines.
5
Pathological examination of patient tissues provides insights into COVID-19 pathophysiology and supports development of evidence-based treatment strategies.
Research Object
COVID-19 (SARS-CoV-2 infection)
Research Subject
Immunopathology, pathophysiological mechanisms, organ-specific tissue damage, and treatment options
Publication Details
Publication Date
2021-02-16
Journal
Publisher
ISSN
Cited by
152
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest